Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Crinetics Pharmaceuticals Inc CRNX

Healthcare Biotechnology
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid... see more

Recent & Breaking News (NDAQ:CRNX)

Crinetics Pharmaceuticals to Participate in September Investor Conferences

GlobeNewswire September 7, 2021

Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer

GlobeNewswire September 2, 2021

Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2021

Crinetics Pharmaceuticals' Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study

GlobeNewswire August 10, 2021

Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners

GlobeNewswire July 29, 2021

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

GlobeNewswire June 28, 2021

Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

GlobeNewswire June 16, 2021

Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 6, 2021

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

GlobeNewswire April 12, 2021

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

GlobeNewswire April 7, 2021

Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire March 30, 2021

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire March 24, 2021

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

GlobeNewswire March 22, 2021

Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

GlobeNewswire March 12, 2021

Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing's Disease (CRN04894) Advances into Phase 1 Study

GlobeNewswire February 4, 2021

Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study

GlobeNewswire February 3, 2021

Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference 

GlobeNewswire January 6, 2021

Crinetics Pharmaceuticals to Participate in December Investor Conferences

GlobeNewswire November 23, 2020

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology

GlobeNewswire November 16, 2020

Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly

GlobeNewswire November 13, 2020